Intelligenome
8955 Interchange Drive
Houston,
TX
77054
United States
Booth: 1986
Home
Press Releases
Press Releases
IGDx Inc (dba IntelliGenome)
(Feb 13, 2024)
IGDX, Inc. develops diagnostic technology for the world’s serious health challenges and our vision is a diagnostic platform that transforms the lives of people impacted by infectious disease. We have developed and validated ultra-sensitive CRISPR-based detection of low abundance nucleic acid in small volume blood samples.
The first commercialization of our technology will be a first one Mycobacterium tuberculosis point-of-care detection test in blood sample, capable of delivering accurate and reliable results in hours. Our CRISPR-based platform will be ready to combat future infectious disease outbreaks ranging from non-Tuberculosis Mycobacterium (NTM) infections and HIV to global challenges posed by SARS and other emerging diseases.
Our team is in pursuit of a future where point-of-care disease diagnosis is not only accurate, affordable and rapid, but also an instrument of positive transformation, particularly in low-and-medium income countries.
×
Close
Send Mail
To :
Message :
Please enter message details.
Character Limit: 500 characters.
Loading ...
×
Close
Appointment Date*
Sunday, Jul 28 2024
Monday, Jul 29 2024
Tuesday, Jul 30 2024
Wednesday, Jul 31 2024
Thursday, Aug 01 2024
Start Time*
1
2
3
4
5
6
7
8
9
10
11
12
:
00
15
30
45
AM
PM
End Time*
1
2
3
4
5
6
7
8
9
10
11
12
:
00
15
30
45
AM
PM
Check My Calendar
Location*
Status*
Your Message
*
Please enter the Message.
Message should be equal to or lesser than 1000 chars.
Comments
Notes should be equal to or lesser than 4000 chars.
Please enter notes
All
Sun Jul, 28
Mon Jul, 29
Tue Jul, 30
Wed Jul, 31
Thu Aug, 01
Legend
Available Timeslot
Scheduled Appointment
Personal Appointments
Appointment Request
Blocked Timeslot
Restricted Timeslot
Cancelled
Declined
Loading ...
×
Close